Patient 2: History of paraganglioma with a left adrenal mass on MR, NETSPOT imaging showed abnormal left adrenal gland uptake consistent with recurrence. Patient 1: Right lower lobe lung mass on CT, NETSPOT showed intense uptake in the area of the mass.
The table below outlines the results of the 5 patients. All patients had suspicion or confirmation of NET’s by clinical presentation and by other diagnostic imaging modalities. Results: Patients age ranged from 5 to 17 years old with a mean of 12 4 females and 1 male. A low-dose non-contrast CT was performed for anatomical localization and attenuation correction. Imaging was obtained from skull base to proximal thigh for 5 minutes per bed position using 2D acquisition. Imaging commenced approximately 60 minutes post administration. Patients were well hydrated prior to administration and asked to void frequently, and to continue this for several hours after the exam. Patients were injected with 0.054 mCi/kg (2 MBq/kq) Gallium-68 NETSPOT, maximum dose of 5.4 mCi (200 MBq) mCi, minimum dose 2 mCi (74MBq). Patients were instructed to pause somatostatin / octreotide therapy. Pediatric patient preparation involved no dietary restrictions. Methods: A total of 5 pediatric patients were imaged. The objective of this abstract presentation is to outline our experience with imaging pediatric patients suspected or confirmed of having a somatostatin receptor positive neuroendocrine tumor (NET). Because of the rarity of NET’s in children and adolescence the amount of experience in imaging such patients are extremely limited. NET’s are extremely rare in children and adolescence, with an incidence rate of 2.8 per million under the age of 30. Gallium- 68 dotatate, a positron-emitting analogue of somatostatin that binds to somatostatin receptors. NETs are rare noncancerous or cancerous tumors that develop in the hormone-producing cells of the body’s neuroendocrine system that have receptors for somatostatin. Objectives: Gallium-68 Dotatate (NETSPOT) is a PET radiotracer for use in the localization of somatostatin receptor positive neuroendocrine tumors (NETs).
0 kommentar(er)
